A phase 1 study of ON 123300 for the treatment of cancer
Phase of Trial: Phase I
Latest Information Update: 24 Oct 2019
Price : $35 *
At a glance
- Drugs ON 123300 (Primary)
- Indications Advanced breast cancer; Cancer
- Focus Adverse reactions
- Sponsors HanX Biopharmaceuticals
- 24 Oct 2019 According to an Onconova Therapeutics media release, The IND has been submitted in China by Han X.
- 13 Nov 2018 According to an Onconova Therapeutics media release, Investigational New Drug (IND) filing is expected to be submitted in the first half of 2019.
- 24 Apr 2018 New trial record